Breaking News
Get 50% Off 0
🚀 ProPicks AI Hits +34.9% Return! Read Now
Close

Grail Inc (GRAL)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Grail's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
15.09 +0.13    +0.84%
14:30:50 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 26,955
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 15.00 - 15.09
Grail 15.09 +0.13 +0.84%

Grail Inc Company Profile

 
Get an in-depth profile of Grail Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

1360

Equity Type

ORD

GRAIL, LLC, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. GRAIL, LLC was formerly known as PSC15, Inc. and changed its name to GRAIL, LLC in January 2016. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, LLC operates as a subsidiary of Illumina, Inc.

Contact Information

Address 1525 O’Brien Drive
Menlo Park, 94025
United States
Phone 833-694-2553
Fax -
Web grail.com

Top Executives

Name Age Since Title
Richard D. Klausner 72 2016 Director
Brian J. Druker 68 - Member of Advisory Board
Gregory L. Summe 68 - Director
Timothy R. Church - - Member of Scientific Advisory Board
Maykin Ho 71 2019 Director
Jeff Dean - - Member of Scientific Advisory Board
Dennis Lo - - Member of Scientific Advisory Board
Xiangmin Cui 56 2017 Director
Charles Swanton 51 - Member of Scientific Advisory Board
Robert Taylor Nelsen 62 2016 Director
Kaye I. Foster-Cheek 64 2017 Director
Robert P. Ragusa 64 2021 CEO & Director
Hal V. Barron 62 2018 Director
William N. Hait 74 - Member of Scientific Advisory Board
Dana P. Goldman - 2020 Member of Scientific Advisory Board
Azra Raza - - Member of Advisory Board
Aashima Gupta 54 - Member of Advisory Board
Otis Webb Brawley 64 - Member of Advisory Board
William J. Chase 56 2024 Director
Mark B. McClellan 60 - Member of Advisory Board
Ankur Dhingra 48 2024 Director
Christina Curtis - - Member of Scientific Advisory Board
Charles E. Dadswell 65 2024 Director
Elias Adam Zerhouni 73 - Member of Advisory Board
Peter Sasieni - - Member of Advisory Board
Steven C. Mizell 64 - Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GRAL Comments

Write your thoughts about Grail Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email